In Brief: Janssen Liazol
Executive Summary
Janssen Liazol: Liarozole fumarate NDA for management of prostate cancer following failure of hormonal therapies submitted on Dec. 20. Liarozole is a differentiating agent that works by increasing retinoic acid in cells and is active against hormone dependent and independent prostate cancer cells, Janssen says...